ArticlemedRxiv : the preprint server for health sciences2026
Multi-trait Polygenic Profiling and Survival Free of Dementia and Disability: Results from the Health and Retirement Study.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Objective: To determine whether a multi-trait polygenic profile for dementia is associated with dementia- and disability-free survival in middle-aged and older adults. Background: Clinical trials of brain health and aging increasingly use holistic, patient-centered outcomes that capture overall health status. Survival free of dementia and disability is one such outcome. We hypothesized that adverse polygenic profiles for dementia would be associated with higher risk of dementia, disability, or death. Design/Methods: We conducted a genetic association study within the Health and Retirement Study, a prospective, nationally representative longitudinal cohort of U.S. adults. Polygenic profiling used the previously validated integrated polygenic risk score for dementia (iPRS-DEM), which incorporates neurodegenerative and vascular genetic components. Participants were categorized as having favorable (≤20th percentile), intermediate (20th-80th percentile), or poor (>80th percentile) polygenic profiles. The primary outcome was a composite of dementia, disability, or death. Cox proportional hazards models were adjusted for age, sex, genetic ancestry, and genetic principal components. Interaction between continuous iPRS-DEM and APOE ε4 status was assessed for 31-year outcome risk. Results: Among 45,234 HRS participants, 15,620 provided DNA samples, 15,565 had genotype data after quality control and imputation, and 14,333 were free of dementia and disability at baseline (median age 55 years; 58% female). Compared with a favorable polygenic profile, intermediate and poor profiles were associated with higher risk of the composite outcome (HR 1.14, 95% CI 1.07-1.21 and HR 1.43, 95% CI 1.26-1.63, respectively). The relative association was strongest for dementia; for poor versus favorable profiles, HRs were 1.58 (95% CI 1.21-2.05) for dementia, 1.43 (95% CI 1.14-1.79) for disability, and 1.33 (95% CI 1.15-1.54) for death. An interaction between continuous iPRS-DEM and APOE ε4 status was observed for 31-year dementia risk (P=0.016). Relative to favorable-profile APOE ε4 non-carriers, dementia risk was highest among participants with a poor profile who were APOE ε4 carriers (HR 2.32, 95% CI 1.73-3.12). Conclusions: Adverse polygenic profiles for dementia were associated with higher composite risk of dementia, disability, or death in a large population-based cohort, with the strongest association observed for dementia. Joint consideration of iPRS-DEM and APOE ε4 further identified individuals at elevated dementia risk. These findings support the potential value of polygenic profiling for risk stratification while highlighting limitations related to ancestry, generalizability, and clinical translation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.